?> How are EpiSwitch markers detected? - DirectorsTalk

Be sure to check our sister interview main ratings news website

How are EpiSwitch markers detected?

Introduction: Getting the basics right

Oxford BioDynamics’ (OBD) EpiSwitch™ biomarker discovery platform combined with their newly enhanced detection technology gives the company valuable quantitative insights into chromosome conformations (DNA protein complexes) that regulate normal and disease biology in individual patients. The company has developed an International Organization for Standardization (ISO) compliant clinical grade testing platform for quantitative real-time Polymerase Chain Reaction (qPCR) experiments and is actively working with their pharmaceutical and biotechnology industry partners to enable their precision medicine
initiatives.

Approved genomic tests and the Federal Drug Administration (FDA)

PCR-based techniques are considered by the FDA as one of the ‘gold-standard’ technologies used for the validation of experimental results, and numerous PCR-based diagnostic assays have been approved in the last decade. In fact, approximately 40% of nucleic acid-based tests and companion diagnostics approved by the FDA through 2017 utilized PCRbased detection methodologies.

Oxford Biodynamics PLC (LON:OBD) was spun out from Oxford University in June 2007 with the aim of translating fundamental scientific advances into a commercialised platform technology and a new generation of biomarkers for cancer, ALS and other diseases.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    X
    LinkedIn
    Oxford BioDynamics

    More articles like this

    Oxford BioDynamics

    What is EpiSwitchTM and how is it used?

    3rd July 2020

    Oxford BioDynamics’ EpiSwitch™ technology is based on epigenetics, mechanisms that alter gene expression without altering the underlying DNA sequence and whose deregulation plays a role in the development of cancer, autoimmune, and neurologic diseases. Although DNA

    Oxford BioDynamics

    Sanders-Brown research highlights form of severe dementia

    1st July 2020

    The long-running study on aging and brain health at the University of Kentucky’s Sanders-Brown Center on Aging (SBCoA) Alzheimer’s Disease Center has once again resulted in important new findings – highlighting a complex and under-recognized form

    Oxford BioDynamics

    Researchers identify new genetic defect linked to ALS

    17th June 2020

    Mutations in the UBQLN2 gene, known to cause amyotrophic lateral sclerosis (ALS), promote the buildup of toxic waste in brain cells by preventing the normal function of two cellular degradation mechanisms, a study has found. In addition to its known role

    Oxford BioDynamics

    New questions about Covid-19

    3rd June 2020

    The coronavirus is known with certainty that it emerged in China in November and has since spread to almost the entire world, where it has infected more than 5 million people and killed at least 356,000. Older adults are more

    Oxford BioDynamics

    EpiSwitch technology selected as biomarker platform for COVID-19

    29th May 2020

    Oxford BioDynamics’ EpiSwitch technology has been chosen as the biomarker platform for prognostic and predictive profiling of COVID-19 patients in the GETAFIX clinical study.Institute of Infection, Immunity and Inflammation, University of Glasgow, and NHS Scotland are

    Oxford BioDynamics

    Rare Diseases Clinical Research Network Opens Online Survey on COVID-19

    21st May 2020

    The Rare Diseases Clinical Research Network (RDCRN) has opened an online survey to better understand how the COVID-19 outbreak is affecting people with rare diseases, their families, and caregivers. Survey questions cover a patient’s physical and mental health, supply of treatments, and

    Oxford BioDynamics

    Pandemic moves ALS Awareness Month events and activities online

    18th May 2020

    ALS Awareness Month has been observed each May since 1992. But this year, the COVID-19 pandemic has forced supporters to rethink ways to raise funds and awareness for amyotrophic lateral sclerosis (ALS). In previous years, May has been full of fundraising and educational activities

    Oxford BioDynamics

    ALS Awareness

    11th May 2020

    “I think it’s time we stop, children, what’s that sound? Everybody look what’s going down.” That call for awareness comes from the song “For What It’s Worth” by Buffalo Springfield. The song’s writer, Stephen Stills, penned the lyrics in

    Oxford BioDynamics

    ALS Awareness Month This May

    6th May 2020

    Within weeks following my ALS diagnosis, I faced my first ALS Awareness Month. At the time, I was still figuring out exactly what I had and how to pronounce amyotrophic lateral sclerosis. Never mind trying to educate others about it. I hated

    Oxford BioDynamics

    Microarray Facility

    29th April 2020

    The purpose-built Oxford Biodynamics Array facility offers a complete sample processing service for Comparative Genome Hybridization (CGH) using the Agilent microarray platform.  Agilent’s flexible SurePrint technology produces high-quality arrays of 60-mer oligonucleotides in a range of

    Oxford BioDynamics

    EpiSwitch biomarker discovery platform

    22nd April 2020

    INTRODUCTION • The EpiSwitch biomarker discovery platform detects systemic changes in the cellular genomic architecture using a microarray and PCR-based biomarker platform (Figure 1)1. It identifies and monitors chromosome conformation signatures (CCSs), key regulatory processes that

    Oxford BioDynamics

    EpiSwitch technology in Alzheimer’s disease

    16th April 2020

    Alzheimer’s disease (AD) is the most common form of dementia, and it accounts for an estimated 60% – 80% of cases. The hallmark pathologies of AD are the progressive accumulation of the protein fragment beta-amyloid (plaques)

    © 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.